ABSTRACT
INTRODUCTION
It is widely accepted that blood coagulation in vivo is initiated during normal haemostasis, as well as during intravascular thrombus formation, when the cell-surface protein, tissue factor (TF); is exposed to the blood as a consequence of vascular injury In addition to its essential role in haemostasis, tissue factor may be also implicated in several pathophysiological processes, such as intracellular signaling, cell proliferation, and inflammation. For these reasons the tissue factor, factorVIIa complex has been the subject of intense research focus .
(1) . The classical cascade/waterfall hypothesis formulated to explain in vitro coagulation organized the ampilification process into the intrinisic and extrinisic pathways. Recent molecular biology and clinical data indicate that tissue factor/factor-VII interaction is the primary cellular initiator of coagulation in vivo. The process of blood coagulation is divided into an initiation phase followed by a propagation phase. The discovery of tissue factor pathway inhibitor further supports the revised theory of coagulation. It is well established that tissue factor is abundantly present in various extravascular tissues, in the adventitia of blood vessels,and in atheroma plaque. Thus in the event of plaque rupture or damage to the blood vessel wall, tissue factor is readily exposed to flowing blood, allowing it to form a complex with circulating factor VIIa in order to activate factor X both directly and indirectly via factor IX. Platelets quickly adhere to the injured site, facilitating localized thrombin formation and subsequent fibrin production .With each new layer of platelets and fibrin that adheres to the injured surface, the exposed tissue factor on the vessel wall, along with the localized circulating factors IX and X that is generated, becomes increasingly isolated from the events near the surface of the growing thrombus. The physical blankting of an injured surface by platelets and fibrin in addition to the release of the platelet tissue factor pathway inhibitor ,prevents factor IXa and factor Xa from diffusing more than a few tens of microns away from the vessel wall,far short of the 3 mm thickness needed for occlusive thrombosis. Thus an alternative factor Xa generating mechanism must be involved that allows for the formation of prothrombinase activity far away from the vessel wall near the front of a growing thrombus. β-thalassemia is a congenital haemolytic disorder that is caused by partial or complete deficiency of β-globin chain synthesis. The standards of care for thalassemic patients have improved in recent years, resulting in doubling of the average life expectancy. As a consequence, additional previously undescribed complications are now being recognized. In particular, profound haemostatic changes have been observed in patients with β-thalassemia major and intermedia, also in patients with α-thalassemia. Iron accumulation and iron mediated organ damage consistently increase the morbidity and mortality of thalassemic patients especially affecting the myocardium and heart.Despite chelation with desferrioxamine or the new oral chelators, still iron overload results in oxidative stress in these patients due to unability to comply sufficiently with the prescribed treatment. This is because the effective chelation regimen is unpleasant and cumbersome and may even alter iron homeostasis.
(11) Another mechanism of producing oxidative stress in β-thalassemia is the excess free α globin chains due to decreased synthesis of β globin which induces oxidative damage to both integral and cytoskeletal proteins. The excess free α haemoglobin chains also influence red blood cells redox mechanism in β-thalassemia.
(12)
The mechanism of the hypercoagulable state in thalassemia has not been fully elucidated, however evidence from studies of other types of haemolytic anemia such as sickle cell disease (SCD) in which thrombosis is also a major clinical entity (13,14) , may be helpful in understanding the etiology of the latter phenomenon. To our knowledge, the TFPI has not been studied in patients with thalassemia.
The aim of the present work was to investigate the pathophysiological role of the TFPI in modulating thalassemia-induced hypercoagulable state and its possible relation to the oxidative status of the disease.
MATERIAL & METHODS
Twenty consecutive patients with β-thalassemia were enrolled in the study. They were 10 males and 10 females with a mean age of 19.20±4.91 years (range 12-31).
Ten healthy age and sex matched individuals served as control. Patients with thalassemia intermedia were excluded from the study as well as patients having hereditary thrombophilia. As regards chelation therapy, desferrioxamine intake was either regular (the patient receives desferrioxamine according to the conventional guidelines, 5 days/week subcutaneously at a dose of 40 mg/kg/day) or intermittent chelation (the patient receives irregular desferrioxamine, only with blood transfusion which is inadequate and is due to lack of compliance by the patient or due to unavailability of the drug). Patients were clinically examined and a laboratory workup was designed to patients and controls : complete blood count (CBC) (15) was determined by a Coulter Counter (Coulter Electronics, Luton, UC), reticulocyte count was determined by the manual method (15) , serum ferritin by ELISA, prothrombin time (PT) and partial thromboplastin time(PTT) were done by the manual method (15) , determination of TFPI by ELISA was done (16) as well as thiobarbituric acid reactive substances (TBARS) as a marker of oxidative stress.
Hepatitis viral markers for HBV and HCV were also done . Tissue factor pathway inhibitor (TFPI) assay was performed using the IMUBIND Total TFPI ELISA kit (product # 849); 222 Railroad Ave. P.O. Box 1165, Greenwich. It is a sandwich ELISA employing a rabbit anti-human TFPI polyclonal antibody as the capture antibody. Diluted plasma samples were incubated in microtest wells precoated with this capture antibody. TFPI was detected using a biotinylated monoclonal antibody specific for the Kunitz domain 1 of TFPI, the subsequent binding of streptavidin conjugated horseradish peroxidase completed the antibody enzyme detection complex which was visualized as a blue colour upon the addition of TMB substrate, sensitivity was increased by the addition of 0.5 M sulfuric acid stop solution; yielding a yellow colour. TFPI levels were determined by measuring sample solution absorbance at 450 nm and then interpolated from the standard curve. This ELISA detected both intact and truncated forms of TFPI. (16) Statistical analysis of data was carried out using SPSS version 10 and p below 0.05 was considered significant.
RESULTS
Clinical examination revealed that ten patients were splenectomized (50%) and ten had variable degrees of splenomegaly (50%). HBs antigen was found in six patients (30%) and HCV in eight patients (40%). No patients had evident thromboembolic events but four patients had evidence of pulmonary hypertension. As regards chelation therapy, desferrioxamine intake was regular in 7 patients (35%), five patients (25%) did not receive any while 8 patients (40%) receive intermittent chelation therapy. Table  (I) shows the haematological data of patients and controls. A statistically significant increase was found in serum ferritin and reticulocyte count in patients versus the control group (p=0.014 & p=0.000 respectively).
A statistically significant decrease in prothrombin activity was observed in patients compared to the control group (t = 0.098, p= 0.000).
As regards the PTT, no significant change was found on comparing both groups (t = 1.535, p = 0.136).
As regards TFPI, higher mean values was found in patient versus control (t = 0.687, p= 0.498) yet it did not reach statistical significance. As for the TBARS (t = 6.115, p = 0.000) a statistically significant increase was observed in patients versus the control group.
Concerning TFPI and chelation therapy (desferroxamine) in thalassemic patients (regular, intermittent or no intake), no statistical differences was observed among patients (table П).
As regards TFPI and spleen (Table Ш) there was also no statistical differences in between splenectomized or non splenectomized patients although splenectomized patients tended to have higher TFPI.
No correlation was observed between TFPI levels and platelet count ( Figure: 
DISCUSSION
The blood coagulation system establishes a delicate balance between the procoagulant and the anticoagulant functions of the blood with the vessel wall, thereby guarding against excesses in either direction to prevent unwanted haemorrhage or thrombosis. This is maintained through the controlled expression of tissue factor which is not likely to be expressed on the normal resting endothelium.
(14)
Activation of vascular endothelium is considered an important facet of inflammation, vasculitis and thrombosis.
(15) There is a strong evidence of endothelial cell activation in thalassemic patients, and vascular complications are more frequent. (16) (17) (18) The infrequent occurrence of significant thrombotic events suggests that thrombosis is largely a subclinical process, only revealed in autopsy findings.
(8) The triggering insult is multifactorial; soluble leucocyte adhesion molecules (19) and von Willebrand factor have been reported to be elevated in thalassemics. Moreover, the serum of thalassemics has been found to induce the expression of these molecules in endothelial cell cultures from normal individuals.
( 19 )
It is well known that induction of soluble intercellular adhesion molecule (sICAM), soluble vascular adhesion molecules (sVCAM) & Eselectin is mediated by tumour necrosis factor-α (TNF-α), Interleukin-1  (IL-1) and that these cytokines are elevated in sera of these patients. migrate through the endothelium into the tissues. (22) In support to this idea, evidence for endothelial activation in β-thalassemia patients was provided in the present work as a significant increase in TFPI, which reflects a compensatory mechanism to overcome the risk for thrombosis in these patients that result from increased tissue factor release from the injured endothelial cells.
In agreement to our findings, de Jonge (23) who studied TFP in endotoxaemia stated that TFPI, inhibits coagulation activation in a dose-dependent manner, and that plasma free TFPI antigen is positively correlated to the total amount of FVIIa and TF.
(24)
In the present study , no statistical difference in TPFI was observed between splenectomized and nonsplenectomized patients which agrees with Kyriakou et al (18) although our splenectomized patients had higher TFPI levels than the nonsplenectomized. This finding could be explained as our patients had thalassemia major and not thalassemia intermedia which is associated with more enhanced capacity to generate thrombin (25) , as these patients receive less frequently blood transfusion .In these patients the percentage deformed RBCs is kept undiluted which explains the higher RBCs aggregability and thrombus generation and hence thrombotic events. confirmed the presence of markers of in vivo activation of coagulation in splenectomized versus nonsplenectomized thalassemic patients . They attributed the hypercoagulability in thalassemic patients to the loss of red cell deformability which produces increased surface expression of anionic phospholipids,phosphatidyle serine (PS)and phosphatidyle ethanolamine (PE). They provide a phospholipid layer that activates coagulation. It is suggested that the preferential clearing of these abnormal RBCs by the splenic macrophages protects against hypercoagulability in thalassemic patients. Moreover, aged RBCs contain higher amounts of (PS) on the outer leaflet of their membranes compared to young cells and this may serve as a signal for their recognition and removal by the reticuloendothelial system of the spleen.
(8)
The fact that the PTT was normal in our study could reflect the integrity of the intrinisic system favouring the hypercoagulability to be mostly mediated by tissue factor pathway. In contrast paradoxically, the prothrombin activity was decreased in our patients which is attributed to liver impairment which is common in these patients.
Regarding the oxidative stress in our patients, TBARS were significantly increased in patients compared to the control which agrees with Meral et al.
(27) who confirmed the elevated TBARS in thalassemic patients as markers of lipid peroxidation. Despite the lack of association between TFPI and TBARS in the present study, yet it does not refute the role of oxidative stress in endothelial activation. This could be explained by the fact that 40% of the patients in the present study did not receive adequate chelation therapy while 35% received regular regimen .Reactive oxygen species initiate nuclear factor Kappa  (NFK) translocation from the cytoplasm to the nucleus of endothelial cells which switches on the transcription of a large number of genes associated with tissue factor, adhesion molecules (28) , cytokines and acute phase proteins. The lack of differences in TFPI which was observed in our patients receiving regular, intermittent or no chelation therapy could be explained by heterogenecity of thalassemia in terms of genotype, age, number and type of transfusion, frequency of infection and degree of iron overload.
In addition, our patients with HCV infection had the highest TFPI (data not shown). A possible explanation is that the increased secretion of TFPI may be a protective compensatory mechanism in response to the direct influence of antiphospholipid antibodies in these patients. In agreement to our findings, Adams et al.
(31) demonstrated a high TFPI in subjects with antiphospholipid syndrome compared to the control, and they confirmed the presence of anti-tissue factor pathway inhibitor activity in these subjects. They added that these antibodies increase TF-like activity in monocytes and endothelial cells, thus altering the balance of the TF pathway with a net increase in thrombin generation and increased thrombotic risk. Moreover, patients with HCV have an immune vasculitis with positive cytoplasmic antineutrophil antibodies that could lead to thrombotic phenomena.
On the other hand no correlation was found between the level of TFPI and platelet count which is known to be higher in splenectomized thalassemic patients. We could explain this discrepancy by the fact that the trigger that releases TF is not merely through platelets activation and release which is well documented in thalassmic but rather is due to endothelial injury.
(32)
To the best of our knowledge, this is the first demonstration of an increased TFPI in thalassemic patients reflecting its pathophysiological role in modulating the hypercoagulable state in these patients. It ensues that thalassemic patients exposed to a transient additive thrombotic risk factor (e.g. surgery, pregnancy or immobilization) should receive prophylactic antithrombotic therapy.
The extrapolation of our data offers a potential insight for transfecting the arterial wall with natural inhibitors of tissue factor: factor VIIa complex such as tissue factor pathway inhibitor, which may result in complete inhibition of local thrombosis without increasing the potentially harmful systemic effects. Additional studies are warranted to determine the efficacy and safety of such approaches in thalassemic patients. 
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